Phillip Md Et Al Frost Acquires 10,000 Shares of OPKO Health (OPK) Stock

OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 10,000 shares of the business’s stock in a transaction dated Monday, June 11th. The shares were acquired at an average cost of $4.22 per share, for a total transaction of $42,200.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $12,950,973.22. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, June 6th, Phillip Md Et Al Frost purchased 30,000 shares of OPKO Health stock. The shares were acquired at an average cost of $4.05 per share, for a total transaction of $121,500.00.
  • On Thursday, May 31st, Phillip Md Et Al Frost purchased 3,900 shares of OPKO Health stock. The shares were acquired at an average cost of $3.76 per share, for a total transaction of $14,664.00.
  • On Friday, May 25th, Phillip Md Et Al Frost purchased 10,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.70 per share, for a total transaction of $37,000.00.
  • On Wednesday, May 23rd, Phillip Md Et Al Frost purchased 40,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.73 per share, for a total transaction of $149,200.00.
  • On Monday, May 21st, Phillip Md Et Al Frost purchased 90,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.82 per share, for a total transaction of $343,800.00.
  • On Friday, May 18th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $4.04 per share, for a total transaction of $404,000.00.
  • On Friday, May 4th, Phillip Md Et Al Frost purchased 26,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.14 per share, for a total transaction of $81,640.00.
  • On Wednesday, May 2nd, Phillip Md Et Al Frost purchased 50,330 shares of OPKO Health stock. The shares were acquired at an average cost of $3.15 per share, for a total transaction of $158,539.50.
  • On Monday, April 30th, Phillip Md Et Al Frost purchased 75,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.08 per share, for a total transaction of $231,000.00.
  • On Wednesday, April 25th, Phillip Md Et Al Frost purchased 55,372 shares of OPKO Health stock. The shares were acquired at an average cost of $2.99 per share, for a total transaction of $165,562.28.

Shares of NASDAQ OPK traded up $0.09 during mid-day trading on Thursday, reaching $4.54. 63,987 shares of the company traded hands, compared to its average volume of 4,916,919. OPKO Health has a fifty-two week low of $2.66 and a fifty-two week high of $7.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.10 and a quick ratio of 0.94. The firm has a market capitalization of $2.36 billion, a PE ratio of -15.74 and a beta of 1.67.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.05. OPKO Health had a negative net margin of 31.27% and a negative return on equity of 8.76%. The business had revenue of $254.90 million for the quarter, compared to analyst estimates of $236.90 million. During the same quarter last year, the business earned ($0.06) earnings per share. The business’s revenue for the quarter was down 4.3% on a year-over-year basis. sell-side analysts anticipate that OPKO Health will post -0.27 earnings per share for the current fiscal year.

A number of research firms recently commented on OPK. ValuEngine upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research lowered shares of OPKO Health from a “buy” rating to a “hold” rating in a research note on Friday, May 25th. BidaskClub upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 12th. Barrington Research reiterated a “buy” rating and set a $7.00 price objective on shares of OPKO Health in a research note on Wednesday, May 9th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $20.00 price objective on shares of OPKO Health in a research note on Tuesday, May 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $10.21.

Institutional investors have recently bought and sold shares of the business. Ellington Management Group LLC acquired a new position in OPKO Health in the fourth quarter worth approximately $112,000. First Trust Advisors LP acquired a new position in OPKO Health in the fourth quarter worth approximately $154,000. Castleview Partners LLC acquired a new position in OPKO Health in the first quarter worth approximately $103,000. Xact Kapitalforvaltning AB acquired a new position in OPKO Health in the fourth quarter worth approximately $179,000. Finally, Stone Ridge Asset Management LLC acquired a new position in OPKO Health in the fourth quarter worth approximately $221,000. Hedge funds and other institutional investors own 24.21% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply